MA33061B1 - Formulations solides orales d'une pyridopyrimidinone - Google Patents

Formulations solides orales d'une pyridopyrimidinone

Info

Publication number
MA33061B1
MA33061B1 MA34115A MA34115A MA33061B1 MA 33061 B1 MA33061 B1 MA 33061B1 MA 34115 A MA34115 A MA 34115A MA 34115 A MA34115 A MA 34115A MA 33061 B1 MA33061 B1 MA 33061B1
Authority
MA
Morocco
Prior art keywords
tar
solid
liquid
pyridopyrimidinone
contained
Prior art date
Application number
MA34115A
Other languages
Arabic (ar)
English (en)
Inventor
Daya Verma
Yue Helen Teng
Rajinder Singh
Dan Thompson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42125930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33061(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33061B1 publication Critical patent/MA33061B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Pyridine Compounds (AREA)
  • Centrifugal Separators (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE FORMULATION PHARMACEUTIQUE SOLIDE ORALE DE (R)-2-AMINO-7-[4-FLUORO-2-(6-MÉTHOXY-PYRIDIN-2-YL)- PHÉNYL]-4-MÉTHYL-7,8-DIHYDRO-6H-PYRIDO[4,3-D]PYRIMIDIN-5-ONE OU DE SON SEL ; ET UN SURFACTANT OU UN ACIDE.
MA34115A 2009-01-29 2010-01-28 Formulations solides orales d'une pyridopyrimidinone MA33061B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14816009P 2009-01-29 2009-01-29
PCT/US2010/022335 WO2010088336A1 (fr) 2009-01-29 2010-01-28 Formulations solides orales d'une pyridopyrimidinone

Publications (1)

Publication Number Publication Date
MA33061B1 true MA33061B1 (fr) 2012-02-01

Family

ID=42125930

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34115A MA33061B1 (fr) 2009-01-29 2010-01-28 Formulations solides orales d'une pyridopyrimidinone

Country Status (22)

Country Link
US (2) US20110287069A1 (fr)
EP (1) EP2391346A1 (fr)
JP (1) JP2012516346A (fr)
KR (1) KR20110115592A (fr)
CN (1) CN102300559A (fr)
AR (1) AR075180A1 (fr)
AU (1) AU2010208270B2 (fr)
BR (1) BRPI1007515A2 (fr)
CA (1) CA2749533A1 (fr)
CO (1) CO6410282A2 (fr)
EC (1) ECSP11011286A (fr)
IL (1) IL213872A0 (fr)
MA (1) MA33061B1 (fr)
MX (1) MX2011007986A (fr)
NZ (1) NZ594035A (fr)
PE (1) PE20120422A1 (fr)
RU (1) RU2011135424A (fr)
SG (2) SG10201500697WA (fr)
TN (1) TN2011000351A1 (fr)
TW (1) TW201031411A (fr)
WO (1) WO2010088336A1 (fr)
ZA (1) ZA201104894B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
WO2012104823A2 (fr) 2011-02-04 2012-08-09 Novartis Ag Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
US20200155455A1 (en) * 2017-04-13 2020-05-21 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (fr) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1998008490A1 (fr) * 1996-09-01 1998-03-05 Pharmos Corporation Coprecipites solides augmentant la biodisponibilite de substances lipophiles
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
CA2474838C (fr) * 2002-02-01 2009-01-06 Pfizer Products Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
EP1845953A1 (fr) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Formes de dosage assurant la liberation controlee et instantanee d'inhibiteurs de proteines de transfert d'ester de cholesteryle et la liberation instantanee d'inhibiteurs de hmg-coa reductase
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2007068615A2 (fr) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Formule de promédicament contre le vhc
CA2666587C (fr) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Nanoparticules micellaires de substances chimiques
EP2146577A1 (fr) * 2007-05-18 2010-01-27 Scidose, Llc Formulations de ziprasidone
AU2008313727A1 (en) * 2007-10-18 2009-04-23 Novartis Ag CSF-1R inhibitors for treatment of cancer and bone diseases

Also Published As

Publication number Publication date
JP2012516346A (ja) 2012-07-19
ECSP11011286A (es) 2011-09-30
TN2011000351A1 (en) 2013-03-27
CN102300559A (zh) 2011-12-28
CO6410282A2 (es) 2012-03-30
AU2010208270B2 (en) 2014-01-16
NZ594035A (en) 2013-09-27
MX2011007986A (es) 2011-08-15
SG10201500697WA (en) 2015-04-29
ZA201104894B (en) 2012-03-28
SG172813A1 (en) 2011-08-29
US20110287069A1 (en) 2011-11-24
AR075180A1 (es) 2011-03-16
KR20110115592A (ko) 2011-10-21
CA2749533A1 (fr) 2010-08-05
EP2391346A1 (fr) 2011-12-07
RU2011135424A (ru) 2013-03-10
PE20120422A1 (es) 2012-05-03
AU2010208270A1 (en) 2011-07-21
TW201031411A (en) 2010-09-01
US20140044788A1 (en) 2014-02-13
IL213872A0 (en) 2011-07-31
WO2010088336A1 (fr) 2010-08-05
BRPI1007515A2 (pt) 2016-02-23

Similar Documents

Publication Publication Date Title
MA33061B1 (fr) Formulations solides orales d'une pyridopyrimidinone
MY165268A (en) Method for separating liquid from suspended matter in a sludge and installation therefor
NZ584944A (en) Passive grease trap with pre-stage for separating solids from waste water
TW200726581A (en) Separating apparatus
MX2011009018A (es) Recuperacion de material para refuerzos de perforacion.
MX2009007307A (es) Procedimiento para el funcionamiento continuo de molienda en seco de un molino triturador vertical y molino triturador vertical.
MY165710A (en) Device for separating a finely divided solid in suspension in a viscous liquid
UA99196C2 (ru) Устройство для выгрузки твердого вещества из резервуара
GB2455239A (en) Fluid separating vessel
MX346461B (es) Planta de separación con tornillo de arquímedes para el tratamiento de lodos.
MY187870A (en) Dust separation device and electric cleaning apparatus
UA106669C2 (uk) Спосіб очищення газового потоку, навантаженого пилом
CL2013002530A1 (es) Aparato para tratamiento de gas de sintesis bruto generado por gasificacion subterranea de carbon ucg, que comprende un separador de liquidos y solidos que contiene una vasija y un filtro de cesta alojado dentro de la seccion de fondo de la vasija, y un sistema de ventilacion; separador, metodo para separar liquidos y solidos del gas de sintesis.
EA201290911A1 (ru) Устройство для улучшенной гравитационной сепарации с использованием близко расположенных каналов
GB2507932A (en) Vibratory screening apparatus
MY167737A (en) Apparatus for recycling resin
MX2018003915A (es) Aparato de dispensación de base de sumidero para combinación de contenedor a granel y bolsa.
GB2547588A (en) Recovery hopper through for vibratory separator and method
BR112016013529A8 (pt) método e depurador úmido para remoção de partículas a partir de gases
MX2019006751A (es) Aparato y metodo para separacion gravitacional de las fases de un liquido de dos fases.
MA33981B1 (fr) Dispositif et procede pour separer une suspension de goudron liquide et pompable, contenant une matiere solide, avec utilisation sans transport de la matiere solide qui y est contenue, separee
CN208716427U (zh) 一种液体石油产品烃类测定器
TH128083B (th) อุปกรณ์และวิธีการสำหรับแยกสารแขวนลอยน้ำมันดินเหลวและสามารถสูบได้ที่มีของแข็งโดยการใช้ที่ไม่มีการส่งของของแข็งที่ถูกแยกที่อยู่ในสารแขวนลอยดังกล่าว
TH128083A (th) อุปกรณ์และวิธีการสำหรับแยกสารแขวนลอยน้ำมันดินเหลวและสามารถสูบได้ที่มีของแข็งโดยการใช้ที่ไม่มีการส่งของของแข็งที่ถูกแยกที่อยู่ในสารแขวนลอยดังกล่าว
FI20080453A (fi) Menetelmä kivihiilituhkan jalostamiseksi erottamalla hiilipitoinen tuote ja ottamalla talteen silikaattisia tuhkatuotteita sekä menetelmällä tuotetun hiilipitoisen hienotuotteen käyttö